Portal de Periódicos da CAPES

Impact of Previous Local Treatment for Prostate Cancer on Subsequent Metastatic Disease

2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 3 Linguagem: Inglês

10.1016/s0022-5347(05)64562-4

1527-3792

Ian M. Thompson, Catherine M. Tangen, Joseph W. Basler, E. David Crawford,

Prostate Cancer Diagnosis and Treatment

No AccessJournal of UrologyCLINICAL UROLOGY: ORIGINAL ARTICLES1 Sep 2002Impact of Previous Local Treatment for Prostate Cancer on Subsequent Metastatic Disease Ian M. Thompson, Catherine Tangen, Joseph Basler, and E. David Crawford Ian M. ThompsonIan M. Thompson More articles by this author , Catherine TangenCatherine Tangen More articles by this author , Joseph BaslerJoseph Basler More articles by this author , and E. David CrawfordE. David Crawford More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64562-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Metastatic prostate cancer, which is the precursor of most deaths from the disease, is treated most commonly with hormonal therapy. Generally the primary tumor is never treated. Due to evidence that controlling other primary neoplasms affects patient survival we examined the impact of radical prostatectomy and radiotherapy on the outcome in patients with metastatic prostate cancer in the context of a randomized clinical trial. Materials and Methods: Southwest Oncology Group Study 8894 randomized 1,286 men with metastatic prostate cancer to orchiectomy and placebo or orchiectomy and flutamide. We performed proportional hazards analysis of variables previously identified to have a significant impact on survival. In this analysis we determined the impact of previous radical prostatectomy or radiotherapy on survival. Results: Previous radical prostatectomy in patients with metastatic prostate cancer was associated with a statistically significant decrease in the risk of death (hazard ratio 0.77, 95% confidence interval 0.53 to 0.89) relative to those who did not undergo earlier prostatectomy. Conversely previous radiotherapy was associated with a greater risk of death in those who had previously undergone prostatectomy and those who received no definitive earlier therapy. Conclusions: It must be stressed that this intriguing observation was a secondary analysis of a phase III study. Nevertheless, it raises the question of whether control of the primary tumor impacts the ultimate outcome in patients with advanced prostate cancer. The suggestion of the role of radical prostatectomy in locally advanced prostate cancer, the now established role of extirpative therapy for renal cell carcinoma and the suggestion of this phenomenon in ovarian carcinoma should prompt further evaluation of this finding in other data sets. It may provide new opportunities for clinical trials. References 1 : Cancer statistics 2001. CA Cancer J Clin2001; 5: 15. Crossref, Google Scholar 2 : Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med1998; 339: 1036. Crossref, Medline, Google Scholar 3 : Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med2001; 345: 1655. Crossref, Medline, Google Scholar 4 : Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst2001; 93: 219. Crossref, Medline, Google Scholar 5 FREQ, PHREG, LIFESTEST and T-TEST procedures. In: SAS/STAT User’s Guide, Version 8. Cary, North Carolina: SAS Institute, 2000 Google Scholar 6 S-PLUS 2000 Guide to Statistics. Seattle: Data Analysis Products Division MathSoft, Inc., vol. 2, chapt. 10, 1999 Google Scholar 7 : Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001; 358: 966. Crossref, Medline, Google Scholar 8 : Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer1993; 71: 3783. Crossref, Medline, Google Scholar 9 : Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst1997; 89: 1429. Crossref, Medline, Google Scholar 10 : Is low serum free testosterone a marker for high grade prostate cancer?. J Urol2000; 163: 824. Link, Google Scholar 11 : Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol1989; 141: 1139. Link, Google Scholar 12 : Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol1999; 72: 278. Crossref, Medline, Google Scholar 13 : Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol1997; 64: 4. Crossref, Medline, Google Scholar 14 : Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol1997; 64: 9. Crossref, Medline, Google Scholar 15 : Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol1983; 61: 413. Medline, Google Scholar 16 : Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol1997; 158: 1460. Link, Google Scholar 17 : Radical prostatectomy for high grade disease: a reevaluation 1994. J Urol1994; 151: 1583. Link, Google Scholar 18 : Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?. J Urol1994; 152: 1843. Link, Google Scholar 19 : Immediate hormonal therapy compared with observation after radical prostatectomy pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 1781. Crossref, Medline, Google Scholar 20 : Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol1999; 161: 1223. Link, Google Scholar 21 : Stage D1 (T1–3, N1–3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology1997; 50: 251. Crossref, Medline, Google Scholar 22 : Clinical-pathologic T3NxM0 prostate cancer: the case for surgery. In: Advanced Therapy of Prostate Disease. Edited by . Ontario, Canada: B. C. Decker2000: 291. Google Scholar 23 : Neoadjuvant zoladex flutamide in bulky non-bulky clinical stage C carcinoma of the prostate. J Urol2001; 165: 330. Google Scholar 24 : Predicting long-term survival, the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys2000; 47: 617. Crossref, Medline, Google Scholar From the University of Texas Health Science Center at San Antonio, Texas, Fred Hutchinson Cancer Research Center, Seattle, Washington, and University of Colorado Health Science Center, Denver, Colorado© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Li X, Xi H, Cheng X, Yu Y, Zhang C, Wang G and Zhou X (2023) Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rateFrontiers in Endocrinology, 10.3389/fendo.2023.1123934, VOL. 14 Shahait M, Hamieh N, Dobbs R, Nguyen T, Alshannaq H, Kim J, El-Fahmawi A, Lee D and Lee D (2022) Comparative Analysis of Primary Prostate Cancer Treatment and Subsequent Metastatic DiseaseFrontiers in Urology, 10.3389/fruro.2022.891798, VOL. 2 Linxweiler J, Hajili T, Saar M, Maßmann C, Junker K and Stöckle M (2022) Einfluss von lokalen Therapiemaßnahmen auf die Biologie des fortschreitenden ProstatakarzinomsInfluence of local treatment on the biology of advanced prostate cancerDer Urologe, 10.1007/s00120-022-01788-6, VOL. 61, NO. 5, (518-525), Online publication date: 1-May-2022. Takagi K, Kawase M, Kato D, Kawase K, Takai M, Iinuma K, Nakane K, Hagiwara N, Yamada T, Tomioka M and Koie T (2022) Robot-Assisted Radical Prostatectomy for Potential Cancer Control in Patients with Metastatic Prostate CancerCurrent Oncology, 10.3390/curroncol29040233, VOL. 29, NO. 4, (2864-2870) Cheng B, Ye S and Bai P (2021) The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysisWorld Journal of Surgical Oncology, 10.1186/s12957-021-02265-8, VOL. 19, NO. 1, Online publication date: 1-Dec-2021. Watanabe K, Kawaguchi G, Ikeda Y, Hara N and Nishiyama T (2021) Multidisciplinary Therapy in Men with Newly Diagnosed Oligometastatic Prostate CancerResearch and Reports in Urology, 10.2147/RRU.S320433, VOL. Volume 13, (565-571) Koura M, Shiota M, Ueda S, Matsumoto T, Kobayashi S, Monji K, Kashiwagi E, Takeuchi A, Inokuchi J, Shiga K, Yokomizo A and Eto M (2021) Prognostic impact of prior local therapy in castration-resistant prostate cancerJapanese Journal of Clinical Oncology, 10.1093/jjco/hyab019, VOL. 51, NO. 7, (1142-1148), Online publication date: 1-Jul-2021. Connor M, Shah T, Smigielska K, Day E, Sukumar J, Fiorentino F, Sarwar N, Gonzalez M, Falconer A, Klimowska-Nassar N, Evans M, Naismith O, Thippu Jayaprakash K, Price D, Gayadeen S, Basak D, Horan G, McGrath J, Sheehan D, Kumar M, Ibrahim A, Brock C, Pearson R, Anyamene N, Heath C, Shergill I, Rai B, Hellawell G, McCracken S, Khoubehi B, Mangar S, Khoo V, Dudderidge T, Staffurth J, Winkler M and Ahmed H (2021) Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trialBMJ Open, 10.1136/bmjopen-2020-042953, VOL. 11, NO. 2, (e042953), Online publication date: 1-Feb-2021. Xue P, Wu Z, Wang K, Gao G, Zhuang M and Yan M (2020) Oncological Outcome of Combining Cytoreductive Prostatectomy and Metastasis-Directed Radiotherapy in Patients with Prostate Cancer and Bone Oligometastases: A Retrospective Cohort StudyCancer Management and Research, 10.2147/CMAR.S270882, VOL. Volume 12, (8867-8873) Connor M, Shah T, Horan G, Bevan C, Winkler M and Ahmed H (2019) Cytoreductive treatment strategies for de novo metastatic prostate cancerNature Reviews Clinical Oncology, 10.1038/s41571-019-0284-3, VOL. 17, NO. 3, (168-182), Online publication date: 1-Mar-2020. Hahn A, Stenehjem D, Alex A, Gill D, Cheng H, Kessler E, Chittoria N, Twardowski P, Vaishampayan U and Agarwal N (2019) Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancerUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2019.01.029, VOL. 37, NO. 6, (352.e19-352.e24), Online publication date: 1-Jun-2019. Zhang Q, Cheng H, Wang Y, Tian Y, Xia J, Wang Y, Zhou X, Meng X, Wang Y, Gu M and Song N (2019) Different therapeutic regimens in the treatment of metastatic prostate cancer by performing a Bayesian network meta-analysisInternational Journal of Surgery, 10.1016/j.ijsu.2019.04.006, VOL. 66, (28-36), Online publication date: 1-Jun-2019. Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W and Joniau S (2019) Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive ReviewEuropean Urology Oncology, 10.1016/j.euo.2018.09.005, VOL. 2, NO. 2, (174-188), Online publication date: 1-Mar-2019. Pansadoro V and Brassetti A Extrafascial robot-assisted laparoscopic radical prostatectomy in locally advanced prostate cancerMinerva Chirurgica, 10.23736/S0026-4733.18.07759-3, VOL. 74, NO. 1 Patel D, Jha S, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Chapin B and Freedland S (2018) Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer HospitalInternational Journal of Urology, 10.1111/iju.13806, VOL. 25, NO. 12, (998-1004), Online publication date: 1-Dec-2018. Babacar S, Aissatou B, Cyrille Z, Amath T, Alioune S, Yaya S, Boubacar F, Denis B, Hamidou Z, Thiapato F, Modou N, Seck N, Babacar D, Ahmed F, Khassim N and Mamadou B (2018) Cancer de la prostate localisé à haut risque de récidive: résultats de la prise chargeAfrican Journal of Urology, 10.1016/j.afju.2018.11.001, VOL. 24, NO. 4, (296-302), Online publication date: 1-Dec-2018. Bektic J and Horninger W (2018) The impact of surgery in oligometastatic prostate cancermemo - Magazine of European Medical Oncology, 10.1007/s12254-018-0456-3, VOL. 11, NO. 4, (305-308), Online publication date: 1-Dec-2018. Beauval J, Loriot Y, Hennequin C, Rozet F, Barthelemy P, Borchiellini D, Schlürmann Constans F, Gross E, Maillet D, Pasticier G, Pignot G, Timsit M, Vincendeau S, Ploussard G and Sargos P (2018) Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUGCritical Reviews in Oncology/Hematology, 10.1016/j.critrevonc.2017.12.012, VOL. 122, (144-149), Online publication date: 1-Feb-2018. Koo K and Dasgupta P (2018) Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive ReviewYonsei Medical Journal, 10.3349/ymj.2018.59.5.567, VOL. 59, NO. 5, (567), . Lee D and Chang S (2018) The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer Genitourinary Cancers, 10.1007/978-3-319-93339-9_9, (193-214), . Dell’Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Karakiewicz P, Shariat S, Montorsi F and Briganti A (2017) New surgical approaches for clinically high-risk or metastatic prostate cancerExpert Review of Anticancer Therapy, 10.1080/14737140.2017.1374858, VOL. 17, NO. 11, (1013-1031), Online publication date: 2-Nov-2017. Sooriakumaran P (2017) Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trialBJU International, 10.1111/bju.13925, VOL. 120, NO. 5B, (E8-E20), Online publication date: 1-Nov-2017. Morgans A and Hussain M (2017) Risk stratification in oligometastatic prostate cancerCurrent Opinion in Urology, 10.1097/MOU.0000000000000439, VOL. 27, NO. 6, (547-552), Online publication date: 1-Nov-2017. Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, Carlsson S, Steineck G and Wiklund N (2017) Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation TherapyEuropean Urology, 10.1016/j.eururo.2017.04.002, VOL. 72, NO. 3, (345-351), Online publication date: 1-Sep-2017. Poelaert F, Verbaeys C, Rappe B, Kimpe B, Billiet I, Plancke H, Decaestecker K, Fonteyne V, Buelens S and Lumen N (2017) Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) TrialUrology, 10.1016/j.urology.2017.02.051, VOL. 106, (146-152), Online publication date: 1-Aug-2017. Parikh R, Byun J, Goyal S and Kim I (2017) Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate CancerThe Prostate, 10.1002/pros.23294, VOL. 77, NO. 6, (559-572), Online publication date: 1-May-2017. Veeratterapillay R, Goonewardene S, Barclay J, Persad R and Bach C (2017) Radical prostatectomy for locally advanced and metastatic prostate cancerThe Annals of The Royal College of Surgeons of England, 10.1308/rcsann.2017.0031, VOL. 99, NO. 4, (259-264), Online publication date: 1-Apr-2017. Metcalfe M, Smaldone M, Lin D, Aparicio A and Chapin B (2017) Role of radical prostatectomy in metastatic prostate cancer: A reviewUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2017.01.001, VOL. 35, NO. 4, (125-134), Online publication date: 1-Apr-2017. Mathieu R, Korn S, Bensalah K, Kramer G and Shariat S (2016) Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?World Journal of Urology, 10.1007/s00345-016-1906-3, VOL. 35, NO. 4, (567-577), Online publication date: 1-Apr-2017. Naik G and Akinyemiju T (2017) Disparities in hospitalization outcomes among African-American and White prostate cancer patientsCancer Epidemiology, 10.1016/j.canep.2016.12.001, VOL. 46, (73-79), Online publication date: 1-Feb-2017. Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, Fujimoto K, Kawanishi H, Sato F, Narita S, Satoh T, Saito H, Sugimoto M, Teishima J, Masumori N, Egawa S, Sakai H, Okada Y, Terachi T and Ogawa O (2016) A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trialInternational Journal of Clinical Oncology, 10.1007/s10147-016-1037-2, VOL. 22, NO. 1, (166-173), Online publication date: 1-Feb-2017. Kim J, Park J and Ham W (2017) The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancerInvestigative and Clinical Urology, 10.4111/icu.2017.58.5.307, VOL. 58, NO. 5, (307), . Clement J and Sweeney C (2017) Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate CancerJournal of Oncology Practice, 10.1200/JOP.2016.018523, VOL. 13, NO. 1, (9-18), Online publication date: 1-Jan-2017. Baroni R (2016) MRI should be routine for all patients with localized prostate cancer? | Opinion: YesInternational braz j urol, 10.1590/s1677-5538.ibju.2016.06.03, VOL. 42, NO. 6, (1062-1064), Online publication date: 1-Dec-2016. Kaushik D, Boorjian S, Thompson R, Eisenberg M, Carlson R, Bergstralh E, Frank I, Gettman M, Tollefson M and Karnes R (2016) Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancerInternational braz j urol, 10.1590/s1677-5538.ibju.2016.0290, VOL. 42, NO. 6, (1091-1098), Online publication date: 1-Dec-2016. Stevens D and Sooriakumaran P (2016) Oligometastatic Prostate CancerCurrent Treatment Options in Oncology, 10.1007/s11864-016-0439-8, VOL. 17, NO. 12, Online publication date: 1-Dec-2016. Costa W and Guimarães G (2016) Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: YesInternational braz j urol, 10.1590/S1677-5538.IBJU.2016.05.04, VOL. 42, NO. 5, (876-879), Online publication date: 1-Oct-2016. Zabell J, Adejoro O, Jarosek S, Elliott S and Konety B (2016) Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysisWorld Journal of Urology, 10.1007/s00345-016-1790-x, VOL. 34, NO. 10, (1397-1403), Online publication date: 1-Oct-2016. Rusthoven C, Jones B, Flaig T, Crawford E, Koshy M, Sher D, Mahmood U, Chen R, Chapin B, Kavanagh B and Pugh T (2016) Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate CancerJournal of Clinical Oncology, 10.1200/JCO.2016.67.4788, VOL. 34, NO. 24, (2835-2842), Online publication date: 20-Aug-2016. Mathieu R, Lucca I, Rouprêt M, Briganti A and Shariat S (2016) The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladderNature Reviews Urology, 10.1038/nrurol.2016.126, VOL. 13, NO. 8, (471-479), Online publication date: 1-Aug-2016. Bernard B, Gershman B, Karnes R, Sweeney C and Vapiwala N (2016) Approach to Oligometastatic Prostate CancerAmerican Society of Clinical Oncology Educational Book, 10.1200/EDBK_159241, NO. 36, (119-129), Online publication date: 1-May-2016. Bayne C, Williams S, Cooperberg M, Gleave M, Graefen M, Montorsi F, Novara G, Smaldone M, Sooriakumaran P, Wiklund P and Chapin B (2016) Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future PerspectivesEuropean Urology, 10.1016/j.eururo.2015.04.036, VOL. 69, NO. 5, (775-787), Online publication date: 1-May-2016. Soulié M, Portier G and Salomon L (2015) Principes oncologiques du contrôle local de la tumeur primitiveProgrès en Urologie, 10.1016/j.purol.2015.07.014, VOL. 25, NO. 15, (918-932), Online publication date: 1-Nov-2015. Satkunasivam R, Kim A, Desai M, Nguyen M, Quinn D, Ballas L, Lewinger J, Stern M, Hamilton A, Aron M and Gill I (2015) Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare AnalysisJournal of Urology, VOL. 194, NO. 2, (378-385), Online publication date: 1-Aug-2015. Stewart S and Boorjian S (2015) Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspectiveUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2014.10.003, VOL. 33, NO. 5, (235-244), Online publication date: 1-May-2015. Koo K, Yoo H, Kim K, Park S, Han K, Rha K, Hong S, Yang S and Chung B (2014) Prognostic Impact of Synchronous Second Primary Malignancies on the Overall Survival of Patients with Metastatic Prostate CancerJournal of Urology, VOL. 193, NO. 4, (1239-1244), Online publication date: 1-Apr-2015.Heidenreich A, Pfister D and Porres D (2014) Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control StudyJournal of Urology, VOL. 193, NO. 3, (832-838), Online publication date: 1-Mar-2015. Heidenreich A, Porres D and Pfister D (2015) The Role of Palliative Surgery in Castration-Resistant Prostate CancerOncology Research and Treatment, 10.1159/000442268, VOL. 38, NO. 12, (670-677), . Heidenreich A, Pfister D, Brehmer B and Porres D (2014) Zytoreduktive radikale Prostatektomie beim Prostatakarzinom mit minimaler ossärer MetastasierungCytoreductive radical prostatectomy for prostate cancer with minimal osseous metastasesDer Urologe, 10.1007/s00120-014-3697-8, VOL. 54, NO. 1, (14-21), Online publication date: 1-Jan-2015. FAIENA I, SINGER E, PUMILL C and KIM I (2014)(2014) Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)International Journal of Oncology, 10.3892/ijo.2014.2656, VOL. 45, NO. 6, (2193-2198), Online publication date: 1-Dec-2014. Piper C, Porres D, Pfister D and Heidenreich A (2014) The role of palliative surgery in castration-resistant prostate cancerCurrent Opinion in Supportive & Palliative Care, 10.1097/SPC.0000000000000078, VOL. 8, NO. 3, (250-257), Online publication date: 1-Sep-2014. Bach C, Pisipati S, Daneshwar D, Wright M, Rowe E, Gillatt D, Persad R and Koupparis A (2014) The status of surgery in the management of high-risk prostate cancerNature Reviews Urology, 10.1038/nrurol.2014.100, VOL. 11, NO. 6, (342-351), Online publication date: 1-Jun-2014. Culp S, Schellhammer P and Williams M (2014) Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based StudyEuropean Urology, 10.1016/j.eururo.2013.11.012, VOL. 65, NO. 6, (1058-1066), Online publication date: 1-Jun-2014. Huber J, Groeben C and Wirth M (2014) Entfernung des Primärtumors bei hämatogen metastasierter TumorerkrankungRemoval of the primary tumor in hematogenous metastatic tumor diseaseDer Urologe, 10.1007/s00120-014-3548-7, VOL. 53, NO. 6, (840-846), Online publication date: 1-Jun-2014. Rusthoven C, Carlson J, Waxweiler T, Raben D, Dewitt P, Crawford E, Maroni P and Kavanagh B (2014) The Impact of Definitive Local Therapy for Lymph Node-Positive Prostate Cancer: A Population-Based StudyInternational Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2014.01.008, VOL. 88, NO. 5, (1064-1073), Online publication date: 1-Apr-2014. Aoun F, Peltier A and van Velthoven R (2014) A Comprehensive Review of Contemporary Role of Local Treatment of the Primary Tumor and/or the Metastases in Metastatic Prostate CancerBioMed Research International, 10.1155/2014/501213, VOL. 2014, (1-12), . Won A, Gurney H, Marx G, De Souza P and Patel M (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancerBJU International, 10.1111/bju.12169, VOL. 112, NO. 4, (E250-E255), Online publication date: 1-Aug-2013. Oderda M, Joniau S, Spahn M and Gontero P (2012) Debulking surgery in the setting of very high-risk prostate cancer scenariosBJU International, 10.1111/j.1464-410X.2012.10942.x, VOL. 110, NO. 6b, (E192-E198), Online publication date: 1-Sep-2012. Qin X, Ma C, Ye D, Yao X, Zhang S, Dai B, Zhang H, Shen Y, Zhu Y, Zhu Y, Shi G, Xiao W, Lin G and Swanson G (2012) Tumor cytoreduction results in better response to androgen ablation—a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancerUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2010.02.010, VOL. 30, NO. 2, (145-149), Online publication date: 1-Mar-2012. Den R and Dicker A (2011) Introduction Signaling Pathways and Molecular Mediators in Metastasis, 10.1007/978-94-007-2558-4_1, (1-10), . Lodde M, Lacombe L and Fradet Y (2010) Salvage Therapy With Bicalutamide 150 mg in Nonmetastatic Castration-resistant Prostate CancerUrology, 10.1016/j.urology.2009.12.057, VOL. 76, NO. 5, (1189-1193), Online publication date: 1-Nov-2010. Stephenson A, Kattan M, Eastham J, Bianco F, Yossepowitch O, Vickers A, Klein E, Wood D and Scardino P (2009) Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen EraJournal of Clinical Oncology, 10.1200/JCO.2008.18.2501, VOL. 27, NO. 26, (4300-4305), Online publication date: 10-Sep-2009. Soulié M, Thoulouzan M, Péneau M, Richaud P and Ravery V (2008) La chirurgie du cancer de la prostate au stade localement avancé. Revue du comité de cancérologie de l’AFU (sous-comité « Prostate »)Progrès en Urologie, 10.1016/j.purol.2008.09.051, VOL. 18, NO. 13, (1031-1037), Online publication date: 1-Dec-2008. Palisaar R and Noldus J (2008) Stellenwert der radikalen Prostatektomie beim lokal fortgeschrittenen ProstatakarzinomThe role of surgery in locally advanced prostate cancerDer Urologe, 10.1007/s00120-008-1721-6, VOL. 47, NO. 11, (1417-1423), Online publication date: 1-Nov-2008. Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M, Eisenberger M, Higano C, Bubley G, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly W, Figg W, Small E, Beer T, Wilding G, Martin A and Hussain M (2008) In ReplyJournal of Clinical Oncology, 10.1200/JCO.2008.17.2494, VOL. 26, NO. 21, (3648-3649), Online publication date: 20-Jul-2008. Mitchell R and Chang S (2008) Current controversies in the treatment of high-risk prostate cancerCurrent Opinion in Urology, 10.1097/MOU.0b013e3282f9b37f, VOL. 18, NO. 3, (263-268), Online publication date: 1-May-2008. Soulié M (2008) What is the Role of Surgery for Locally Advanced Disease?European Urology Supplements, 10.1016/j.eursup.2007.12.006, VOL. 7, NO. 5, (400-405), Online publication date: 1-Apr-2008. Stenzl A and Merseburger A (2008) Radical Prostatectomy in Advanced-Stage and -Grade Disease: Cure, Cytoreduction, or Cosmetics?European Urology, 10.1016/j.eururo.2007.10.048, VOL. 53, NO. 2, (234-236), Online publication date: 1-Feb-2008. Makarov D, Humphreys E, Mangold L, Carducci M, Partin A, Eisenberger M, Walsh P and Trock B (2007) The Natural History of Men Treated With Deferred Androgen Deprivation Therapy in Whom Metastatic Prostate Cancer Developed Following Radical ProstatectomyJournal of Urology, VOL. 179, NO. 1, (156-162), Online publication date: 1-Jan-2008. van der Poel H, Beetsma D, van Boven H and Horenblas S (2007) Perineal Salvage Prostatectomy for Radiation Resistant Prostate CancerEuropean Urology, 10.1016/j.eururo.2006.08.011, VOL. 51, NO. 6, (1565-1572), Online publication date: 1-Jun-2007. Yossepowitch O, Bianco F, Eggener S, Eastham J, Scher H and Scardino P (2007) The Natural History of Noncastrate Metastatic Prostate Cancer after Radical ProstatectomyEuropean Urology, 10.1016/j.eururo.2006.10.045, VOL. 51, NO. 4, (940-948), Online publication date: 1-Apr-2007. Gontero P, Marchioro G, Pisani R, Zaramella S, Sogni F, Kocjancic E, Mondaini N, Bonvini D, Tizzani A and Frea B (2007) Is Radical Prostatectomy Feasible in All Cases of Locally Advanced Non-Bone Metastatic Prostate Cancer? Results of a Single-Institution StudyEuropean Urology, 10.1016/j.eururo.2006.08.050, VOL. 51, NO. 4, (922-930), Online publication date: 1-Apr-2007. Halabi S, Vogelzang N, Ou S and Small E (2018) The Impact of Prior Radical Prostatectomy in Men With Metastatic Castration Recurrent Prostate Cancer: A Pooled Analysis of 9 Cancer and Leukemia Group B TrialsJournal of Urology, VOL. 177, NO. 2, (531-534), Online publication date: 1-Feb-2007. Wilson S (2006) Genitourinary malignanciesUpdate on Cancer Therapeutics, 10.1016/j.uct.2006.08.007, VOL. 1, NO. 4, (443-466), Online publication date: 1-Dec-2006. Dorff T, Quek M, Daneshmand S and Pinski J (2014) Evolving treatment paradigms for locally advanced and metastatic prostate cancerExpert Review of Anticancer Therapy, 10.1586/14737140.6.11.1639, VOL. 6, NO. 11, (1639-1651), Online publication date: 1-Nov-2006. Swanson G, Thompson I, Basler J and Crawford E (2018) Metastatic Prostate Cancer—Does Treatment of the Primary Tumor Matter?Journal of Urology, VOL. 176, NO. 4, (1292-1298), Online publication date: 1-Oct-2006.Carver B, Bianco F, Scardino P and Eastham J (2018) Long-Term Outcome Following Radical Prostatectomy in Men With Clinical Stage T3 Prostate CancerJournal of Urology, VOL. 176, NO. 2, (564-568), Online publication date: 1-Aug-2006. Berglund R, Jones J, Ulchaker J, Fergany A, Gill I, Kaouk J and Klein E (2006) Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysisUrology, 10.1016/j.urology.2005.12.003, VOL. 67, NO. 6, (1253-1256), Online publication date: 1-Jun-2006. Canby-Hagino E, Swanson G, Crawford E, Basler J, Hernandez J and Thompson I (2005) Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?Current Prostate Reports, 10.1007/s11918-005-0009-1, VOL. 3, NO. 4, (153-159), Online publication date: 1-Dec-2005. Stephenson A and Eastham J (2005) Role of Salvage Radical Prostatectomy for Recurrent Prostate Cancer After Radiation TherapyJournal of Clinical Oncology, 10.1200/JCO.2005.03.1468, VOL. 23, NO. 32, (8198-8203), Online publication date: 10-Nov-2005. Canby-Hagino E, Swanson G, Crawford E, Basler J, Hernandez J and Thompson I (2005) Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?Current Urology Reports, 10.1007/s11934-005-0006-5, VOL. 6, NO. 3, (183-189), Online publication date: 1-Jun-2005. Maroni P and Crawford E (2005) Surgical Management of Prostate Cancer: Optimizing Patient Selections and Clinical OutcomeSurgical Oncology Clinics of North America, 10.1016/j.soc.2004.11.009, VOL. 14, NO. 2, (301-319), Online publication date: 1-Apr-2005. Johnson M, Iversen P, Schwier P, Corn A, Sandusky G, Graff J and Neubauer B (2005) Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) modelThe Prostate, 10.1002/pros.20148, VOL. 62, NO. 4, (322-338), Online publication date: 1-Mar-2005. Wilson S and Crawford E (2005) Genitourinary malignancies , 10.1016/S0921-4410(04)22022-1, (485-513), . SWANSON G, RIGGS M and EARLE J (2018) FAILURE AFTER PRIMARY RADIATION OR SURGERY FOR PROSTATE CANCER: DIFFERENCES IN RESPONSE TO ANDROGEN ABLATIONJournal of Urology, VOL. 172, NO. 2, (525-528), Online publication date: 1-Aug-2004. Zaramella S, Monesi G, Sala M, Favro M, Marchioro G, Gontero P, Kocjancic E, Ceratti G, Pisani R, Maso G and Frea B (2018) Morbility and Outcomes of Radical Prostatectomy in Patients with Clinically Advanced Prostatic CancerUrologia Journal, 10.1177/039156030407100316, VOL. 71, NO. 3, (244-246), Online publication date: 1-Jul-2004. Arrizabalaga moreno M, García gonzález J, Pérez garnelo M and Paniagua andrés P (2004) Alternativas terapéuticas en el cáncer de próstata localizado. Experiencia sobre 454 pacientesActas Urológicas Españolas, 10.1016/S0210-4806(04)73104-6, VOL. 28, NO. 6, (418-431), Online publication date: 1-Jan-2004. Cho D, Di Blasio C, Rhee A and Kattan M (2003) Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)Urologic Oncology: Seminars and Original Investigations, 10.1016/S1078-1439(03)00057-7, VOL. 21, NO. 4, (282-291), Online publication date: 1-Jul-2003. Volume 168 Issue 3 September 2002 Page: 1008-1012 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsprostateprostatic neoplasmsneoplasm metastasissurvivalprostatectomyMetrics Author Information Ian M. Thompson More articles by this author Catherine Tangen More articles by this author Joseph Basler More articles by this author E. David Crawford More articles by this author Expand All Advertisement PDF downloadLoading ...